Yes, abnormal methylation patterns can serve as biomarkers for cancer diagnosis, prognosis, and therapy response. For example, the methylation status of the MGMT gene is used to predict the response to alkylating agents in glioblastoma patients. Similarly, the detection of hypermethylated DNA in body fluids like blood or urine can serve as a non-invasive method for early cancer detection.
